Patient-Centric Services
Expanded Access Programs
Marken transports and delivers investigational medical products that have not yet been approved by the FDA for use by patients who face a life-threatening or critical illness and who receive special exemptions for the unapproved treatments. Early access programs, also known as compassionate use, expedite the transport of these products is extremely time and temperature sensitive and often requires alternative transport solutions including, but not limited to, on-board courier and charter services, a specialized delivery by a dedicated Marken team.
Related resources
Marken: Patient-Centric Supply Chain Solutions
14 April 2023
Patient, doctor and industry interest continues to shift dramatically towards siteless and hybrid clinical trials. Marken’s comprehensive suite of patient-centric…
Light the Way Forward With Marken
13 April 2023
Each year, we are inspired by your dedication to find cures and ease conditions for patients. To continue the momentum…
Marken Delivers Lifesaving Intravenous Therapy from Pennsylvania to Sites Across the USA Within 24 Hours
9 February 2023
Marken successfully delivered the time-critical intravenous therapy, Legalon, from its GMP Philadelphia depot to sites across the USA to treat…
Marken Successfully Delivers Lifesaving Apheresis Treatment From The USA to the UK Within 24 Hours
9 February 2023
Marken was tasked with performing a next-day collection of temperature-sensitive tumor material from Philadelphia to Manchester, UK for an urgent…
Revolutionizing Patient-Centric Supply Chains to Improve Vaccine Access
7 February 2023
Global disruptions over the past several years have had an undeniable impact on the vaccine landscape, including research trends, risk…
Happy Holidays from Marken
21 December 2022
At Marken, we are passionate about patients – always finding a way to deliver for our clients – on-time, within…
Marken Successfully Ships Lifesaving Treatments For Humanitarian Aid In Ukraine
24 June 2022
Marken successfully transported critical compassionate use medicinal products and supplies as part of a humanitarian effort in Ukraine. Mitigating the…
Decentralized Trial Logistics Requires Thoughtful Strategy: Marken
22 September 2021
Outsourcing Pharma and Marken President Ariette van Strien discuss the complexity of decentralized trials and considerations for crafting a strategic…
The Ultimate Patient-Centric Supply Chain
16 July 2021
From two-hour grocery delivery to telehealth visits, consumers have come to expect convenience, immediacy and personalization from everyday service providers….
Decentralized Trials Call for Supply Chain Flexibility: Marken
8 April 2021
Outsourcing-Pharma and Marken’s Vice President, Clinical Distribution, Cell and Gene Therapy Supply Chain, Nina Vas, and Senior Director of Global…
Compelling Advantages of Creating a Patient-Centric Supply Chain
8 February 2021
Only a clinical trial supply chain partner that exhibits global regulatory and trade compliance proficiency and transports shipments in a…
Marken Makes It Happen COVID-19
13 October 2020
In these unprecedented times, we are coming together to achieve one shared goal: to beat COVID-19. The Marken team is…
Understanding why we must adapt, continuously asking ourselves how we can change what matters is how we keep on delivering it.
Login and quick links